Drug news
Florbetaben Imaging Tracer is sold by Bayer to Piramel Imaging SA
Bayer HealthCare has sold its molecular imaging business including world rights of florbetaben to Piramal Imaging SA a subsidiary of Indian company Piramal Health Care. Florbetaben is currently in development for the detection of beta-amyloid plaques in the brain, which are one of two pathological hallmarks of Alzheimer's Disease,